Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR011 in ALL after HSCT
NCT03327285Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2018
- Primary completion
- Feb 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of C-CAR011 in acute lymphoblastic leukemia (ALL), sponsored by Peking University People's Hospital. Primary endpoints: Treatment-Emergent Adverse Events at 2 months and Graft-versus-Host Disease at 2 months. Status: unknown.
02
Drugs
C-CAR011
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03327285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03327285.